M.D. Ph.D. David D. Chang - 02 Feb 2026 Form 4 Insider Report for Allogene Therapeutics, Inc. (ALLO)

Signature
/s/Earl Douglas, Attorney-in-Fact
Issuer symbol
ALLO
Transactions as of
02 Feb 2026
Net transactions value
-$171,484
Form type
4
Filing time
04 Feb 2026, 17:18:18 UTC
Previous filing
18 Mar 2025

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Chang David D President and CEO, Director 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO /s/Earl Douglas, Attorney-in-Fact 04 Feb 2026 0001611024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLO Common Stock Sale $171,484 -95,269 -1.8% $1.80 5,185,862 02 Feb 2026 Direct F1, F2, F3
holding ALLO Common Stock 856,044 02 Feb 2026 See footnote F4
holding ALLO Common Stock 856,044 02 Feb 2026 See footnote F5
holding ALLO Common Stock 1,201,108 02 Feb 2026 See footnote F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLO Stock Option (Right to buy) Award $0 +1,387,931 $0.000000 1,387,931 02 Feb 2026 Common Stock 1,387,931 $1.87 Direct F7
transaction ALLO Restricted Stock Unit Award $0 +392,586 $0.000000 392,586 02 Feb 2026 Common Stock 392,586 Direct F8
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the number of shares sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. This sale is mandated by the Issuer's election under its equity incentive plan to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary trade by the reporting person.
F2 The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $1.71 to $1.87, inclusive. The reporting person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F3 Includes 4,562 shares of the Issuer's common stock acquired by the reporting person on September 15, 2025 pursuant to an employee stock purchase program.
F4 Securities held in the name of the RTC 2019 Trust dated October 1, 2019.
F5 Securities held in the name of the JEC 2019 Trust dated October 1, 2019.
F6 Securities held in the name of the Chang 2006 Family Trust
F7 25% of the shares subject to the stock option shall vest on February 2, 2027, and the remaining shares shall vest in 36 equal monthly installments thereafter.
F8 Represents an award of Restricted Stock Units (RSUs). Each RSU represents a contingent right to receive one share of the Companys Common Stock. The RSUs will vest in 4 successive equal annual installments over the four-year period measured from February 2, 2026, subject to continued service through the vesting date.